Delcath Systems (NASDAQ:DCTH) Receives New Coverage from Analysts at Craig Hallum

Craig Hallum started coverage on shares of Delcath Systems (NASDAQ:DCTH) in a research report sent to investors on Friday, Marketbeat.com reports. The brokerage issued a buy rating and a $18.00 price target on the stock.

A number of other equities research analysts have also commented on DCTH. StockNews.com upgraded Delcath Systems to a sell rating in a research report on Wednesday, March 27th. HC Wainwright increased their price objective on shares of Delcath Systems from $20.00 to $22.00 and gave the stock a buy rating in a research note on Wednesday, May 15th. Finally, Stephens started coverage on shares of Delcath Systems in a research report on Tuesday, May 14th. They set an overweight rating and a $25.00 target price for the company. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and a consensus price target of $19.83.

Delcath Systems Trading Up 1.7 %

NASDAQ DCTH opened at $8.37 on Friday. The stock has a market cap of $232.60 million, a P/E ratio of -3.16 and a beta of 0.60. Delcath Systems has a 12-month low of $2.25 and a 12-month high of $9.18. The company has a fifty day simple moving average of $6.83 and a two-hundred day simple moving average of $5.19.

Delcath Systems (NASDAQ:DCTH) last issued its earnings results on Tuesday, May 14th. The company reported ($0.43) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.43). The company had revenue of $3.14 million during the quarter, compared to analyst estimates of $3.70 million. Delcath Systems had a negative return on equity of 290.07% and a negative net margin of 1,080.72%. As a group, sell-side analysts forecast that Delcath Systems will post -1.31 earnings per share for the current year.

Hedge Funds Weigh In On Delcath Systems

Several large investors have recently made changes to their positions in DCTH. Levin Capital Strategies L.P. increased its holdings in Delcath Systems by 12.2% in the first quarter. Levin Capital Strategies L.P. now owns 54,969 shares of the company’s stock valued at $262,000 after buying an additional 5,969 shares in the last quarter. WealthPlan Investment Management LLC purchased a new position in shares of Delcath Systems in the 4th quarter valued at about $73,000. Vanguard Group Inc. raised its holdings in Delcath Systems by 31.0% in the 1st quarter. Vanguard Group Inc. now owns 683,686 shares of the company’s stock worth $3,261,000 after purchasing an additional 161,678 shares during the period. Armistice Capital LLC purchased a new position in Delcath Systems during the third quarter worth approximately $664,000. Finally, BVF Inc. IL grew its holdings in Delcath Systems by 23.1% in the first quarter. BVF Inc. IL now owns 1,202,067 shares of the company’s stock valued at $5,734,000 after purchasing an additional 225,918 shares during the period. 61.12% of the stock is currently owned by institutional investors and hedge funds.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.